Topiramate effectiveness in Prader-Willi syndrome.
Prader-Willi syndrome is a neurologic disorder caused by a mutation on chromosome 15. It is characterized by short stature, obesity, mild-to-moderate mental retardation, and multiple behavior problems including mood, self-abusive behavior, and compulsive-eating disorder. These behaviors have detrimental effects on the mental and physical health of patients with Prader-Willi syndrome. This study evaluates the effectiveness of a new antiepileptic medication, topiramate, on behavior, mood, and compulsive-eating disorder associated with Prader-Willi syndrome. Recent studies have indicated that topiramate affects behavior, as well as reducing appetite and weight in some patients. We evaluated seven patients with Prader-Willi syndrome and determined that, in these patients, topiramate appeared to have a positive effect on reducing self-abusive behavior, improving mood, and stabilizing weight.
Smathers
Sarah A
SA
Michigan Institute for Neurological Disorders, Farmington Hills, Michigan 48334, USA.
Wilson
Jacquelyn G
JG
Nigro
Michael A
MA
D000293:Adolescent; D000339:Affect / Q000187:drug effects; D000927:Anticonvulsants / Q000008:administration & dosage* / Q000009:adverse effects; D002648:Child; D003192:Compulsive Behavior / Q000188:drug therapy* / Q000209:etiology; D005247:Feeding Behavior / Q000187:drug effects; D005260:Female; D005632:Fructose / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives*; D006801:Humans; D008297:Male; D011218:Prader-Willi Syndrome / Q000150:complications / Q000188:drug therapy*; D012528:Satiety Response / Q000187:drug effects; D000077236:Topiramate; D016896:Treatment Outcome; D015431:Weight Loss / Q000187:drug effects
D000927:Anticonvulsants; D000077236:Topiramate; D005632:Fructose